Navigation Links
Halozyme Therapeutics to Present at Upcoming Investor Conferences
Date:10/22/2008

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at three upcoming investor conferences:

-- BIOCOM Investor Conference to be held at the Hyatt Regency in La Jolla, Calif. on Monday, October 27, 2008 at 2:00 p.m. PDT (5:00 p.m. EDT);

-- Oppenheimer's 19th Annual Healthcare Conference to be held at the Waldorf-Astoria Hotel in New York on Monday, November 3, 2008 at 10:40 a.m. EST (7:40 a.m. PST); and

-- Lazard Capital Markets 5th Annual Healthcare Conference to be held at the St. Regis Hotel in New York on Tuesday, November 18, 2008 at 2:40 p.m. EST (11:40 a.m. PST).

Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the internet by visiting the Investor Relations section of Halozyme's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation dates.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of additional enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Halozyme Contact Media Contacts

Robert H. Uhl Karen Sparks / Joleen Schultz

Senior Director, Investor Relations Mentus

(858) 704-8264 (858) 455-5500, x275/x215

ruhl@halozyme.com karen@mentus.com jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics to Host Research Day for Investors and Analysts
2. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
7. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
8. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
9. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
10. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
Breaking Biology News(10 mins):